Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | A2B395 |
Synonyms | |
Therapy Description |
A2B395 comprises allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting EGFR, and containing an HLA-A*02-targeted LIR-1-based inhibitory receptor, and shRNA targeting beta2 microglobulin (B2M), which potentially induce killing of tumor cells expressing EGFR with loss of heterozygosity for HLA-A*02 (J Clin Oncol 2025 43: 16_suppl, TPS2677, NCI Drug Dictionary). |